Manhattan Scientifics(MHTX)
$0.000.00 (0.00%)
MHTX
Manhattan Scientifics financials statements
$0.00
At close:0.00 (0.00%)
Manhattan Scientifics (MHTX) Ratios
26 Followers
Manhattan Scientifics Ratios
MHTX's free cash flow for Q2 2024 was $-17.00K. For the 2024 fiscal year, MHTX's free cash flow was increased by $0.00 and operating cash flow was $-17.00K. See a summary of the company’s cash flow.
| Ratios | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.03 | 0.11 | 0.40 | 0.66 | 0.27 |
| Quick Ratio | 0.03 | 0.11 | 0.62 | 0.95 | 0.42 |
| Cash Ratio | 0.03 | 0.10 | 0.17 | 0.35 | 0.12 |
| Solvency Ratio | -0.55 | -1.00 | -1.50 | 1.99 | -0.38 |
| Operating Cash Flow Ratio | -0.09 | -0.21 | -0.31 | -0.38 | -0.15 |
| Short-Term Operating Cash Flow Coverage | -3.17 | -3.17 | -3.24 | 0.00 | 0.00 |
| Net Current Asset Value | $ -2.05M | $ -2.54M | $ -1.87M | $ -1.51M | $ -2.66M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.19 | 0.11 | 0.04 | 0.02 | 0.04 |
| Debt-to-Equity Ratio | -0.03 | -0.06 | 0.13 | 0.02 | -0.08 |
| Debt-to-Capital Ratio | -0.03 | -0.07 | 0.11 | 0.02 | -0.08 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.02 | -0.08 |
| Financial Leverage Ratio | -0.18 | -0.61 | 3.34 | 1.47 | -2.21 |
| Debt Service Coverage Ratio | -19.40 | -20.66 | -23.15 | 173.64 | -243.00 |
| Interest Coverage Ratio | 0.00 | -32.33 | -26.42 | -27.00 | -205.00 |
| Debt to Market Cap | 0.04 | 0.02 | 0.01 | 0.00 | 0.01 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.01 | 0.02 | 0.03 | -0.06 | 0.15 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | 0.00% | -5418.00% | -7226.00% | 8678.00% | -1254.64% |
| EBITDA Margin | 0.00% | -5412.00% | -7222.00% | 8682.00% | -1252.58% |
| Operating Profit Margin | 0.00% | -1358.00% | -1374.00% | -1350.00% | -1056.70% |
| Pretax Profit Margin | 0.00% | -5460.00% | -7278.00% | 8628.00% | -1259.79% |
| Net Profit Margin | 0.00% | -5460.00% | -7278.00% | 8628.00% | -1259.79% |
| Continuous Operations Profit Margin | 0.00% | -5460.00% | -7278.00% | 8628.00% | -1259.79% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 165.72% | 402.06% | 529.69% | -639.11% | 119.22% |
| Return on Assets (ROA) | -368.67% | -264.79% | -105.36% | 63.00% | -54.92% |
| Return on Equity (ROE) | 64.65% | 161.06% | -351.59% | 92.30% | 121.59% |
| Return on Capital Employed (ROCE) | 39.01% | 106.59% | -32.82% | -11.57% | -782.44% |
| Return on Invested Capital (ROIC) | 40.36% | 128.84% | -30.90% | -11.57% | -782.44% |
| Return on Tangible Assets | -368.67% | -264.79% | -105.36% | 63.00% | -54.92% |
| Earnings Yield | -80.12% | -61.02% | -40.67% | 18.12% | -21.18% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.17 | 0.17 | 0.32 |
| Payables Turnover | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 50.00 | 12.50 | 8.33 | 24.25 |
| Asset Turnover | 0.00 | 0.05 | 0.01 | 0.01 | 0.04 |
| Working Capital Turnover Ratio | 0.00 | -0.04 | -0.09 | -0.05 | -0.06 |
| Cash Conversion Cycle | -48545.00 | 0.00 | 2190.00 | 2190.00 | 1128.87 |
| Days of Sales Outstanding | 0.00 | 0.00 | 2190.00 | 2190.00 | 1128.87 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 48545.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 2190.00 | 2190.00 | 1128.87 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | -97.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | -97.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -3.17 | -3.17 | -3.24 | -3.73 | -4.05 |
| Operating Cash Flow to Sales Ratio | 0.00 | -6.98 | -8.42 | -7.76 | -3.26 |
| Free Cash Flow Yield | -13.07% | -7.80% | -4.70% | -1.65% | -5.48% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.25 | -1.64 | -2.46 | 5.52 | -4.72 |
| Price-to-Sales (P/S) Ratio | 0.00 | 89.48 | 178.97 | 476.25 | 59.47 |
| Price-to-Book (P/B) Ratio | -0.81 | -2.64 | 8.65 | 5.09 | -5.74 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -7.65 | -12.82 | -21.26 | -60.75 | -18.25 |
| Price-to-Operating Cash Flow Ratio | -7.65 | -12.82 | -21.26 | -61.37 | -18.25 |
| Price-to-Earnings Growth (PEG) Ratio | 0.02 | 0.07 | 0.01 | -0.01 | 0.05 |
| Enterprise Value Multiple | -1.24 | -1.63 | -2.45 | 5.43 | -4.60 |
| Enterprise Value | 1.45M | 4.41M | 8.85M | 23.56M | 5.59M |
| EV to EBITDA | -1.24 | -1.63 | -2.45 | 5.43 | -4.60 |
| EV to Sales | 0.00 | 88.18 | 176.93 | 471.27 | 57.58 |
| EV to Free Cash Flow | -7.62 | -12.63 | -21.01 | -60.11 | -17.68 |
| EV to Operating Cash Flow | -7.62 | -12.63 | -21.01 | -60.73 | -17.68 |
| Tangible Book Value Per Share | -0.00 | -0.00 | 0.00 | 0.01 | -0.00 |
| Shareholders’ Equity Per Share | -0.00 | -0.00 | 0.00 | 0.01 | -0.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.00 | -0.00 | -0.01 | 0.01 | -0.00 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.01 | 1.01 | 0.99 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.22 | 0.20 | 0.22 | 0.08 |
| SG&A to Revenue | 0.00 | 14.36 | 14.54 | 14.28 | 11.48 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.48 | 3.78 |
| Income Quality | 0.16 | 0.13 | 0.12 | -0.09 | 0.26 |
Currency in USD
